Overview
Background
Peter Simpson is a recognised expert in the molecular and pathological characterisation of breast and lung cancers. His research is based at the UQ Centre for Clinical Research (UQCCR), where he is the Head of the Cancer Theme and is a Research Group Leader in Cancer Genomics. He has published >150 articles (>12,000 citations, H-index 52; Scopus, May2025) including in Nature, Nature Medicine, Annals of Oncology and the American Journal of Respiratory and Critical Care Medicine. He co-manages the Brisbane Breast Bank (BBB), a tissue bank created to facilitate clinical breast cancer research, and the Debutant lung cancer Program.
Pete also holds a teaching appointment in UQ, where he is passionate about the science and clinical applications of Pathology. He teaches into the UQ Medical Program (Year 1 and 2), as well as to undergraduates. He has co-authored a chapter ‘Breast Diseases’ in the latest edition (11th) of the internationally acclaimed Medical text book Robbins and Cotran Pathologic Basis of Disease.
Outside UQ, Pete is a Fellow of the Faculty of Science in the Royal College of Pathologists of Australasia (FFSc RCPA), a member of the kConFab Executive (https://www.kconfab.org/), a member of the Lobular Breast Cancer Alliance Scientific Advisory Board (https://lobularbreastcancer.org/), and a member of the International Cancer Genome Consortium (Breast Cancer group).
Pete enjoys supervising students at all levels in their careers and collaborating within multidisciplinary teams spanning clinical (e.g. pathology, oncology) and science teams (e.g. in ‘omics, bioinformatics and machine learning).
Availability
- Associate Professor Peter Simpson is:
- Available for supervision
- Media expert
Fields of research
Qualifications
- Doctor of Philosophy, University of Liverpool
Research interests
-
Broad Research Program
Cancer is a very heterogeneous disease, making morphological classification and management of patients a significant challenge. Despite great advances it remains difficult to predict which patients are at risk of their disease returning (recurrence), spreading (metastasis) or which patients will gain most benefit to specific therapies. There has therefore been a concerted effort to supplement the morphological classification of disease with molecular data that can provide a clearer appreciation for this complexity and better predict tumour behaviour. This ideology has driven significant advancements in the field of molecular pathology research. My research program embraces these advances in technology to help better understand mechanisms of disease development and progression and help improve the molecular aspects of diagnosis and patient management. Themes of research involve 1) invasive lobular carcinoma of the breast, 2) breast cancer diagnosed in young individuals, and 3) lung cancer.
-
Invasive Lobular Carcinoma
Invasive Lobular Carcinoma (ILC) is the most commonly diagnosed ‘special’ morphological type of breast cancer, comprising up to 15% of all cases. The most important biological feature of lobular breast cancer is the functional loss of cell adhesion molecule E-cadherin. This is the glue that holds epithelial cells together. Loss of E-cadherin leads to a growth pattern that can be diffuse and highly invasive through the breast tissue. This leads to a number of important clinical challenges with diagnosing and managing this cancer: the cancer can be hard to palpate or detect by mammographic screening and hard to fully excise during surgery; if the cancer spreads it can again be hard to detect. A large component of Peter's research focuses on aspects of this specific cancer subtype, including understanding molecular determinants that predict tumour behaviour and prognosis, and mechanisms of invasion and metastasis.
-
Familial Breast Cancer
Family history is a significant risk factor for the development of breast cancer, often leading to early diagnosis of disease. For some families, the genetic component of this risk is well understood and attributed to pathogenic germline variants in moderate-high risk genes (e.g. BRCA1, BRCA2, PALB2, TP53, ATM, CHEK2). For many families the underlying genetic risk is unknown. Further, some individuals develop breast cancer at a young age when they have no family history. We study clinical samples using a variety of molecular profiling techniques, including whole genome sequencing and digital spatial transcriptomics, and we are interested in understanding the germline and somatic molecular mechanism that contribute to the development of disease. This work is a collaboration with several tissue banks: kConFab, the BBB and the Australian Breast Cancer Tissue Bank.
-
Lung Cancer Diagnostics
Lung Cancer has the highest mortality of all cancers. Most cases are diagnosed at an advance, inoperable stage and so are associated with a poor prognosis. Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) sampling is an important procedure to make a tissue diagnosis of disease and to provide specimens for molecular testing. Next generation sequencing is an important component of diagnostic practice and therapeutic decision making for lung cancer patients. Our program of work is focused on optimising molecular testing strategies from different types of cancer samples (tissue, supernatant, cfDNA) to improve the success of testing for patients. This is a collaboration with A/Prof David Fielding (https://about.uq.edu.au/experts/9060) from the Department of Thoracic Medicine (RBWH), plus colleagues from Pathology Queensland, QIMR Berghofer and a network of hospitals around Australia.
Research impacts
Breast cancer is the most diagnosed cancer in women worldwide and consequently is the biggest contributor to morbidity and mortality from cancer.
My work in the field of breast cancer genomics has sought to unravel molecular mechanisms driving the evolution of disease, from early lesions through to treatment resistance and metastatic progression. Our work uses various types of ‘omics applications, including whole genome sequencing and spatial transcriptomics, married with detailed cancer morphology assessment. Gene mutations and mutational signature analysis in the context of sporadic and familial breast cancer has revealed pathogenic germline mutations, different mechanisms of genomic evolution and clonal heterogeneity. The work through the International Cancer Genome Consortium contributed to the development of HRDetect (Nature Medicine) for therapeutic decision making.
My work in lobular breast cancer has an international standing. As a research community, we aim to raise the profile of lobular breast cancer as an important, common and yet understudied type of breast cancer. We have demonstrated this disease is in fact a heterogenous subtype, exhibiting morphological variants and diverse genomic features. We developed LobSig as a potential prognostic tool for lobular breast cancer, which is undergoing further validation. We have a program of work to better understand the biology of disease and identify tissue- and blood-based biomarkers of disease progression.
Lung cancer is the highest mortality rate of all cancers worldwide. The Debutant lung cancer clinical research program was established in 2018 and has sought to optimise and expand lung cancer molecular testing applications. The work has been funded by various sources, including Pathology Queensland, Royal Brisbane & Women’s Hospital Foundation, Cancer Council Qld, Cancer Australia, Australian Genomics and the Medical Research Future Fund (MRFF). The work has demonstrated the clinical utility of very small cytology samples and blood (cfDNA) samples using comprehensive genomic assays. The translation of results from this Program could significantly enhance the number of patients eligible for targeted therapies.
Works
Search Professor Peter Simpson’s works on UQ eSpace
2026
Book Chapter
The breast
Sokolova, Anna, Simpson, Peter T. and Lakhani, Sunil R. (2026). The breast. Robbins, Cotran & Kumar pathologic basis of disease. (pp. 944-969) edited by Jon C. Aster, Abul K. Abbas, Vinay Kumar, Jayanta Debnath and Abhijit Das. Philadelphia, PA United States: Elsevier.
2025
Journal Article
Integrated profiling of metaplastic breast cancer identifies putative master regulators of intratumoral heterogeneity
Feng, Yufan, Xiong, Albert, Mulay, Onkar, Sokolova, Anna, Lim, Malcolm, Van Haeringen, Benjamin, McGuire, Natasha, de Luca, Xavier, Simpson, Peter T., Nguyen, Quan, Lakhani, Sunil R. and McCart Reed, Amy E. (2025). Integrated profiling of metaplastic breast cancer identifies putative master regulators of intratumoral heterogeneity. npj Breast Cancer, 11 (1) 89, 1. doi: 10.1038/s41523-025-00807-x
2025
Journal Article
ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection
Sokolova, Anna, Joshi, Vaibhavi, Chittoory, Haarika, Walsh, Michael, Lim, Malcolm, Kutasovic, Jamie R., Ferguson, Kaltin, Simpson, Peter T., Lakhani, Sunil R. and Reed, Amy E. McCart (2025). ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection. Histopathology, 87 (2), 223-234. doi: 10.1111/his.15465
2025
Conference Publication
Enhancing sensitivity and specificity of the CA15-3 (MUC1) breast cancer assay by detection of N-glycolylneuraminic acid (Neu5Gc) using the lectin SubB2M
Nikseresht, Sara, Khanabdali, Ramin, Shewell, Lucy, Day, Christopher, McCart Reed, Amy, Jennings, Michael, Haarika, Haarika, Sunil, Sunil, Simpson, Peter, Nabiee, Romina, Moore, Mathew, Hinch, Leearne and Rice, Gregory (2025). Enhancing sensitivity and specificity of the CA15-3 (MUC1) breast cancer assay by detection of N-glycolylneuraminic acid (Neu5Gc) using the lectin SubB2M. AACR Annual Meeting 2025, Chicago, IL United States, 25-30 April 2025. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2025-lb407
2025
Journal Article
A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates with poor survival in breast cancer
Miranda, Mariska, Saunus, Jodi M., Akgül, Seçkin, Marjaneh, Mahdi Moradi, Kutasovic, Jamie R., Shi, Wei, Chatterjee, Oishee, Casciello, Francesco, Rozali, Esdy, Handoko, Herlina Y., Wiegmans, Adrian P., Liu, Tianqing, Lee, Jason S., Day, Bryan W., Edwards, Stacey L., French, Juliet D., McCart Reed, Amy E., Chenevix-Trench, Georgia, Khanna, Kum Kum, Simpson, Peter T., Lakhani, Sunil R. and Al-Ejeh, Fares (2025). A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates with poor survival in breast cancer. Fortune Journal of Health Sciences, 250-266. doi: 10.26502/fjhs.271
2025
Journal Article
Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay
Nikseresht, S., Shewell, L. K., Day, C. J., Jennings, M. P., Chittoory, H., McCart Reed, A. E., Simpson, P. T., Lakhani, S. R., Nabiee, R., Moore, M., Khanabdali, R., Hinch, L. M. and Rice, G. E. (2025). Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay. Breast Cancer Research and Treatment, 211 (3) 188534, 1-11. doi: 10.1007/s10549-025-07672-z
2025
Journal Article
Hormonal contraception and breast cancer risk for carriers of germline mutations in BRCA1 and BRCA2
Phillips, Kelly-Anne, Kotsopoulos, Joanne, Domchek, Susan M., Terry, Mary Beth, Chamberlain, James A., Bassett, Julie K., Aeilts, Amber M., Andrulis, Irene L., Buys, Saundra S., Cui, Wanda, Daly, Mary B., Eisen, Andrea F., Foulkes, William D., Friedlander, Michael L., Gronwald, Jacek, Hopper, John L., John, Esther M., Karlan, Beth Y., Kim, Raymond H., Kurian, Allison W., Lubinski, Jan, Metcalfe, Kelly, Nathanson, Katherine L., Singer, Christian F., Southey, Melissa C., Symecko, Heather, Tung, Nadine, Narod, Steven A., Milne, Roger L. ... Zaheed, Milita (2025). Hormonal contraception and breast cancer risk for carriers of germline mutations in BRCA1 and BRCA2. Journal of Clinical Oncology, 43 (4), 422-431. doi: 10.1200/JCO.24.00176
2025
Journal Article
Clinically boosting cancer molecular targeted radioligand therapies with innovative nanomaterials
Lim, Malcom, Simpson, Peter T., Lakhani, Sunil R., Masud, Mostafa, Puttick, Simon, Rose, Stephen, Roberts, Matthew J. and Koo, Kevin M. (2025). Clinically boosting cancer molecular targeted radioligand therapies with innovative nanomaterials. ChemNanoMat, 11 (1) e202400449. doi: 10.1002/cnma.202400449
2024
Journal Article
Performance of somatic structural variant calling in lung cancer using Oxford Nanopore sequencing technology
Liu, Lingchen, Zhang, Jia, Wood, Scott, Newell, Felicity, Leonard, Conrad, Koufariotis, Lambros T., Nones, Katia, Dalley, Andrew J., Chittoory, Haarika, Bashirzadeh, Farzad, Son, Jung Hwa, Steinfort, Daniel, Williamson, Jonathan P., Bint, Michael, Pahoff, Carl, Nguyen, Phan T., Twaddell, Scott, Arnold, David, Grainge, Christopher, Simpson, Peter T., Fielding, David, Waddell, Nicola and Pearson, John V. (2024). Performance of somatic structural variant calling in lung cancer using Oxford Nanopore sequencing technology. BMC Genomics, 25 (1) 898, 1-13. doi: 10.1186/s12864-024-10792-3
2024
Journal Article
Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset
Davidson, Aimee L., Michailidou, Kyriaki, Parsons, Michael T., Fortuno, Cristina, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Naven, Marc, Abubakar, Mustapha, Ahearn, Thomas U., Alonso, M. Rosario, Andrulis, Irene L., Antoniou, Antonis C., Auvinen, Päivi, Behrens, Sabine, Bermisheva, Marina A., Bogdanova, Natalia V., Bojesen, Stig E., Brüning, Thomas, Byers, Helen J., Camp, Nicola J., Campbell, Archie, Castelao, Jose E., Cessna, Melissa H., Chang-Claude, Jenny, Chanock, Stephen J., Chenevix-Trench, Georgia, Sahlberg, Kristine K., Børresen-Dale, Anne-Lise ... kConFab Investigators (2024). Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset. The American Journal of Human Genetics, 111 (9), 2059-2069. doi: 10.1016/j.ajhg.2024.07.004
2024
Conference Publication
LobSig4 is a superior and readily implementable ILC-focussed prognostic biomarker set
Kalinowski, Lauren, Kutasovic, Jamie, Srihari, Sriganesh, Feng, Yufan, Lal, Samir, Ferguson, Kaltin, Chittoory, Haarika, Sokolova, Anna, Lim, Malcolm, De Croft, Priyakshi Kalita, Lakhani, Sunil, Simpson, Peter and Reed, Amy McCart (2024). LobSig4 is a superior and readily implementable ILC-focussed prognostic biomarker set. San Antonio Breast Cancer Symposium 2023, San Antonio, TX United States, 5-9 December 2023. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.sabcs23-po3-15-09
2024
Journal Article
B7-H3 expression in breast cancer and brain metastasis
Joshi, Vaibhavi, Beecher, Kate, Lim, Malcolm, Stacey, Andrew, Feng, Yufan, Jat, Parmjit S., Duijf, Pascal H. G., Simpson, Peter T., Lakhani, Sunil R. and McCart Reed, Amy E. (2024). B7-H3 expression in breast cancer and brain metastasis. International Journal of Molecular Sciences, 25 (7) 3976, 1-17. doi: 10.3390/ijms25073976
2024
Journal Article
Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) samples from advanced non-small cell lung cancer for whole genome, whole exome and comprehensive panel sequencing
Fielding, David, Lakis, Vanessa, Dalley, Andrew J., Chittoory, Haarika, Newell, Felicity, Koufariotis, Lambros T., Patch, Ann-Marie, Kazakoff, Stephen, Bashirzadeh, Farzad, Son, Jung Hwa, Ryan, Kimberley, Steinfort, Daniel, Williamson, Jonathan P., Bint, Michael, Pahoff, Carl, Nguyen, Phan Tien, Twaddell, Scott, Arnold, David, Grainge, Christopher, Pattison, Andrew, Fairbairn, David, Gune, Shailendra, Christie, Jemma, Holmes, Oliver, Leonard, Conrad, Wood, Scott, Pearson, John V., Lakhani, Sunil R., Waddell, Nicola ... Nones, Katia (2024). Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) samples from advanced non-small cell lung cancer for whole genome, whole exome and comprehensive panel sequencing. Cancers, 16 (4) 785. doi: 10.3390/cancers16040785
2024
Journal Article
NDRG1 is a prognostic biomarker in breast cancer and breast cancer brain metastasis
Joshi, Vaibhavi, Stacey, Andrew, Feng, Yufan, Kalita‐de Croft, Priyakshi, Duijf, Pascal H.G., Simpson, Peter T., Lakhani, Sunil R. and McCart Reed, Amy E. (2024). NDRG1 is a prognostic biomarker in breast cancer and breast cancer brain metastasis. The Journal of Pathology: Clinical Research, 10 (2) e12364, 1-16. doi: 10.1002/2056-4538.12364
2023
Journal Article
Targeted hyperbranched nanoparticles for delivery of doxorubicin in breast cancer brain metastasis
Lim, Malcolm, Fletcher, Nicholas L., Saunus, Jodi M., McCart Reed, Amy E., Chittoory, Haarika, Simpson, Peter T., Thurecht, Kristofer J. and Lakhani, Sunil R. (2023). Targeted hyperbranched nanoparticles for delivery of doxorubicin in breast cancer brain metastasis. Molecular Pharmaceutics, 20 (12), 6169-6183. doi: 10.1021/acs.molpharmaceut.3c00558
2023
Journal Article
Discrepancies in tumor mutation burden reporting from sequential endobronchial ultrasound transbronchial needle aspiration samples within single lymph node stations - brief report
Fielding, David, Dalley, Andrew J., Singh, Mahendra, Nandakumar, Lakshmy, Lakis, Vanessa, Chittoory, Haarika, Fairbairn, David, Patch, Ann-Marie, Kazakoff, Stephen H., Ferguson, Kaltin, Bashirzadeh, Farzad, Bint, Michael, Pahoff, Carl, Son, Jung Hwa, Ryan, Kimberley, Hodgson, Alan, Sharma, Sowmya, Pearson, John V., Waddell, Nicola, Lakhani, Sunil R., Hartel, Gunter, Simpson, Peter T. and Nones, Katia (2023). Discrepancies in tumor mutation burden reporting from sequential endobronchial ultrasound transbronchial needle aspiration samples within single lymph node stations - brief report. Frontiers in Oncology, 13 1259882, 1-10. doi: 10.3389/fonc.2023.1259882
2023
Journal Article
Deep spatial-omics analysis of Head & Neck carcinomas provides alternative therapeutic targets and rationale for treatment failure
Causer, Andrew, Tan, Xiao, Lu, Xuehan, Moseley, Philip, Teoh, Siok M., Molotkov, Natalie, McGrath, Margaret, Kim, Taehyun, Simpson, Peter T., Perry, Christopher, Frazer, Ian H., Panizza, Benedict, Ladwa, Rahul, Nguyen, Quan and Gonzalez-Cruz, Jazmina L. (2023). Deep spatial-omics analysis of Head & Neck carcinomas provides alternative therapeutic targets and rationale for treatment failure. n p j Precision Oncology, 7 (1) 89, 1-13. doi: 10.1038/s41698-023-00444-2
2023
Journal Article
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Morra, Anna, Schreurs, Maartje A. C., Andrulis, Irene L., Anton-Culver, Hoda, Augustinsson, Annelie, Beckmann, Matthias W., Behrens, Sabine, Bojesen, Stig E., Bolla, Manjeet K., Brauch, Hiltrud, Broeks, Annegien, Buys, Saundra S., Camp, Nicola J., Castelao, Jose E., Cessna, Melissa H., Chang-Claude, Jenny, Chung, Wendy K., Sahlberg, Kristine K., Børresen-Dale, Anne-Lise, Gram, Inger Torhild, Olsen, Karina Standahl, Engebråten, Olav, Naume, Bjørn, Geisler, Jürgen, Grenaker Alnæs, Grethe I., Colonna, Sarah V., Couch, Fergus J., Cox, Angela, Cross, Simon S. ... Hooning, Maartje J. (2023). Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. Cancer Medicine, 12 (15), 16142-16162. doi: 10.1002/cam4.6272
2023
Journal Article
Obesity-associated changes in molecular biology of primary breast cancer
Nguyen, Ha-Linh, Geukens, Tatjana, Maetens, Marion, Aparicio, Samuel, Bassez, Ayse, Borg, Ake, Brock, Jane, Broeks, Annegien, Caldas, Carlos, Cardoso, Fatima, De Schepper, Maxim, Delorenzi, Mauro, Drukker, Caroline A., Glas, Annuska M., Green, Andrew R., Isnaldi, Edoardo, Eyfjörð, Jórunn, Khout, Hazem, Knappskog, Stian, Krishnamurthy, Savitri, Lakhani, Sunil R., Langerod, Anita, Martens, John W. M., McCart Reed, Amy E., Murphy, Leigh, Naulaerts, Stefan, Nik-Zainal, Serena, Nevelsteen, Ines, Neven, Patrick ... Desmedt, Christine (2023). Obesity-associated changes in molecular biology of primary breast cancer. Nature Communications, 14 (1) 4418. doi: 10.1038/s41467-023-39996-z
2023
Journal Article
Whole genome sequencing in advanced lung cancer can be performed using diff-quik cytology smears derived from endobronchial ultrasound, transbronchial needle aspiration (EBUS TBNA)
Fielding, David, Dalley, Andrew J., Singh, Mahendra, Nandakumar, Lakshmy, Lakis, Vanessa, Chittoory, Haarika, Fairbairn, David, Ferguson, Kaltin, Bashirzadeh, Farzad, Bint, Michael, Pahoff, Carl, Son, Jung Hwa, Hodgson, Alan, Pearson, John V., Waddell, Nicola, Lakhani, Sunil R., Hartel, Gunter, Nones, Katia and Simpson, Peter T. (2023). Whole genome sequencing in advanced lung cancer can be performed using diff-quik cytology smears derived from endobronchial ultrasound, transbronchial needle aspiration (EBUS TBNA). Lung, 201 (4), 407-413. doi: 10.1007/s00408-023-00631-9
Funding
Current funding
Supervision
Availability
- Associate Professor Peter Simpson is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Applications of Molecular Genetics in Translational Breast Cancer Research
Associate Advisor
Other advisors: Associate Professor Amy McCart Reed, Professor Sunil Lakhani
-
Doctor Philosophy
Investigating therapeutic vulnerabilities in breast cancer.
Associate Advisor
Other advisors: Professor Sunil Lakhani, Associate Professor Amy McCart Reed
-
Doctor Philosophy
Breast cancer metastasis prediction via machine learning and spatial cellular pathology
Associate Advisor
Other advisors: Dr Nan Ye, Dr Quan Nguyen
-
Doctor Philosophy
Developing optimal transport models for spatial and single cell data to understand cancer progression
Associate Advisor
Other advisors: Professor Jessica Mar, Dr Quan Nguyen
-
Doctor Philosophy
Circulating biomarkers in invasive lobular breast carcinoma
Associate Advisor
Other advisors: Professor Sunil Lakhani, Associate Professor Amy McCart Reed
Completed supervision
-
2025
Doctor Philosophy
Studies on the utility of Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS TBNA) samples in novel investigations of lung cancer genomics, and immune responses
Principal Advisor
Other advisors: Professor Sunil Lakhani
-
2021
Doctor Philosophy
Multi-omics: Leveraging omics data integration to identify dysregulated biology in breast cancer
Principal Advisor
Other advisors: Associate Professor Amy McCart Reed, Dr Katia Nones
-
2018
Doctor Philosophy
Genomic and transcriptomic biomarkers of prognosis in invasive lobular breast cancer.
Principal Advisor
Other advisors: Associate Professor Amy McCart Reed, Professor Sunil Lakhani
-
2016
Doctor Philosophy
Intratumour heterogeneity in the development and progression of breast cancer
Principal Advisor
Other advisors: Associate Professor Amy McCart Reed, Professor Sunil Lakhani
-
2016
Doctor Philosophy
Computational analysis of DNA repair pathways in breast cancer
Associate Advisor
Other advisors: Honorary Professor Kum Kum Khanna
-
2016
Doctor Philosophy
Identification of new prognostic biomarker for triple negative breast cancer
Associate Advisor
Other advisors: Dr Jodi Saunus, Professor Sunil Lakhani
-
2013
Doctor Philosophy
A Search For Novel Cancer Susceptibility Genes
Associate Advisor
Other advisors: Professor Sunil Lakhani, Professor Melissa Brown
-
2013
Doctor Philosophy
Clinical-Pathological and Molecular Analysis to Understand Breast Cancer Progression
Associate Advisor
Other advisors: Professor Sunil Lakhani
Media
Enquiries
Contact Associate Professor Peter Simpson directly for media enquiries about their areas of expertise.
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: